<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30155">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01976117</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-ENO-2009-21</org_study_id>
    <nct_id>NCT01976117</nct_id>
  </id_info>
  <brief_title>E-nose Utility in the Diagnosis of Bacterial Infection in COPD</brief_title>
  <official_title>E-nose Utility in the Diagnosis of Bacterial Infection in Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: A commercial e-nose (Cyranose 320) is able to detect specific breathprints from
      patients with COPD and bacterial infection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty to 50% of COPD patients have airway colonization with potentially pathogenic
      bacteria. This is associated with worse prognosis. Currently, diagnosis of bacterial
      colonization relies mainly upon quantitative sputum culture. However, this method lacks good
      sensitivity. The electronic nose is a novel device made up of nanosensors capable of
      detecting specific volatile organic compounds (VOCs). OBJECTIVES: Main 1) To assess the
      usefulness of the electronic nose  in the diagnosis of bacterial colonization in COPD.
      Secondary 1) To define the VOCs pattern associated with bacterial colonization. 2) To study
      the pattern of pulmonary and systemic inflammation associated with bacterial colonization as
      well its relationship with the aforementioned VOCs  patterns.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Breathprint in exhaled breath from patients with COPD</measure>
    <time_frame>Day 1</time_frame>
    <description>Breathprints will be assessed by discriminant analysis on principal component reduction, resulting in cross-validated accuracy values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breathprint in exhaled breath from COPD patients with bacterial colonization</measure>
    <time_frame>Day 1</time_frame>
    <description>Breathprints will be assessed by discriminant analysis on principal component reduction, resulting in cross-validated accuracy values</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>Pulmonary Disease, Chronic Obstructive (COPD)</condition>
  <arm_group>
    <arm_group_label>enose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>enose</intervention_name>
    <arm_group_label>enose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD patients

        Exclusion Criteria:

          -  Exacerbation in the last 4 weeks
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oriol Sibila, PhD</last_name>
    <phone>+34935565968</phone>
    <phone_ext>5968</phone_ext>
    <email>osibila@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oriol Sibila, PhD</last_name>
      <phone>+34935565968</phone>
      <phone_ext>5068</phone_ext>
      <email>osibila@santpau.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <lastchanged_date>October 29, 2013</lastchanged_date>
  <firstreceived_date>October 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
